source
- Zura Bio’s Phase 2 trial of tibulizumab fails, shares plungeZura Bio announced that its experimental drug tibulizumab did not meet efficacy endpoints in a Phase 2 study of a painful skin disorder. The company said that both dose levels performed no better t…
- Kyorin signs $140M deal for Japan rights to Edesa's ARDS antibodyKyorin Pharmaceutical will pay $12 million up front and up to $134 million in milestones, plus royalties, for exclusive Japan rights to Edesa Biotech’s anti‑TLR4 antibody, paridiprubart, intended f…